Alpha Family Trust Buys 9,430 Shares of Bristol-Myers Squibb (NYSE:BMY)

Alpha Family Trust boosted its stake in Bristol-Myers Squibb (NYSE:BMY) by 101.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 18,760 shares of the biopharmaceutical company’s stock after acquiring an additional 9,430 shares during the quarter. Alpha Family Trust’s holdings in Bristol-Myers Squibb were worth $971,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. First Foundation Advisors increased its position in Bristol-Myers Squibb by 20.1% in the 1st quarter. First Foundation Advisors now owns 3,270 shares of the biopharmaceutical company’s stock valued at $177,000 after acquiring an additional 548 shares during the period. Acadian Asset Management LLC increased its position in Bristol-Myers Squibb by 76.1% in the 1st quarter. Acadian Asset Management LLC now owns 620,324 shares of the biopharmaceutical company’s stock valued at $33,632,000 after acquiring an additional 268,006 shares during the period. Catalytic Wealth RIA LLC increased its position in Bristol-Myers Squibb by 33.1% in the 1st quarter. Catalytic Wealth RIA LLC now owns 9,086 shares of the biopharmaceutical company’s stock valued at $493,000 after acquiring an additional 2,258 shares during the period. Covestor Ltd increased its position in Bristol-Myers Squibb by 22.4% in the 1st quarter. Covestor Ltd now owns 5,558 shares of the biopharmaceutical company’s stock valued at $302,000 after acquiring an additional 1,019 shares during the period. Finally, Bahl & Gaynor Inc. increased its position in Bristol-Myers Squibb by 2.7% in the 1st quarter. Bahl & Gaynor Inc. now owns 44,568 shares of the biopharmaceutical company’s stock valued at $2,417,000 after acquiring an additional 1,183 shares during the period. Institutional investors own 76.41% of the company’s stock.

Insider Activity

In other Bristol-Myers Squibb news, EVP Samit Hirawat acquired 1,830 shares of Bristol-Myers Squibb stock in a transaction dated Friday, November 1st. The stock was purchased at an average cost of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares of the company’s stock, valued at $3,395,499.03. This represents a 3.04 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Phil M. Holzer sold 700 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on BMY. BMO Capital Markets upped their price target on shares of Bristol-Myers Squibb from $57.00 to $61.00 and gave the company a “market perform” rating in a research report on Tuesday, November 12th. Morgan Stanley upped their price target on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research report on Tuesday, November 12th. Jefferies Financial Group increased their price objective on shares of Bristol-Myers Squibb from $49.00 to $51.00 and gave the stock a “hold” rating in a research report on Wednesday, August 28th. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 29th. Finally, Citigroup increased their price objective on shares of Bristol-Myers Squibb from $55.00 to $60.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 12th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, two have given a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $54.07.

Bristol-Myers Squibb Stock Down 3.9 %

NYSE:BMY opened at $56.22 on Friday. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24. The firm has a fifty day simple moving average of $52.73 and a two-hundred day simple moving average of $47.25. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $61.08.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The firm had revenue of $11.89 billion during the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The business’s revenue was up 8.4% on a year-over-year basis. During the same period last year, the company earned $2.00 earnings per share. As a group, sell-side analysts expect that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 1st. Stockholders of record on Friday, October 4th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.27%. The ex-dividend date was Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is currently -66.85%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.